This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Marios Tanos Joel Dunning Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanos, M. Articles by Dunning, J. Search for Related Content PubMed PubMed Citation Articles by Tanos, M. Articles by Dunning, J. Related Collections Cardiac - pharmacology Cardiac - other Education

Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery?

^a Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle-upon-Tyne, UK
^b Department of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, UK

*Corresponding author. Tel./fax: +44 780 1548122.

E-mail address: joeldunning{at}doctors.org.uk (J. Dunning).

A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether use of Recombinant Activated Factor VII could help haemostasis for intractable bleeding, and decrease blood or blood product requirements in patients undergoing cardiac surgery without excessive risk from thrombosis. Altogether 129 papers were identified using the reported search strategy of which 13 represented the best evidence on the topic. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that Factor VIIa has proven efficacy and safety in over 400,000 uses worldwide outside the cardiothoracic surgical arena, mostly in haemophiliacs. Results from this experience show a 1% risk of serious thrombotic complications. In the cardiothoracic literature, there have been more than 160 reports of its use for intractable bleeding and the serious complication rate is again around 1–2%. In addition, it has been found to be highly efficacious in 80–90% of cases with a single dose of 60–90 µg/kg, which can be repeated after 2–4 h. Thus, for patients with intractable bleeding post cardiac surgery refractory to conventional haemostatic interventions, Factor VIIa is recommended and its complication rates are low.

Key Words: Evidence-based medicine; Factor VIIa; Haemostasis; Bleeding; Blood products; Thoracic surgery

This article has been cited by other articles:

				R. P. Chalwin, R. Tiruvoipati, and G. J. Peek Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 685 - 686. [Abstract] [Full Text] [PDF]

				J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]